| Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the … AJM Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ... The Lancet Haematology 3 (5), e217-e227, 2016 | 530 | 2016 |
| Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS … AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, P La Rosée, ... The Lancet Haematology 4 (11), e510-e523, 2017 | 308 | 2017 |
| Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma ND Doolittle, A Korfel, MA Lubow, E Schorb, U Schlegel, S Rogowski, ... Neurology 81 (1), 84-92, 2013 | 174 | 2013 |
| High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) K Fritsch, B Kasenda, E Schorb, P Hau, J Bloehdorn, R Möhle, S Loew, ... Leukemia 31 (4), 846-852, 2017 | 154 | 2017 |
| High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial G Illerhaus, B Kasenda, G Ihorst, G Egerer, M Lamprecht, U Keller, ... The Lancet Haematology 3 (8), e388-e397, 2016 | 153 | 2016 |
| Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study B Kasenda, E Schorb, K Fritsch, J Finke, G Illerhaus Annals of oncology 23 (10), 2670-2675, 2012 | 128 | 2012 |
| Transfusion-transmitted hepatitis E in Germany, 2013 D Huzly, M Umhau, D Bettinger, T Cathomen, F Emmerich, P Hasselblatt, ... Eurosurveillance 19 (21), 20812, 2014 | 117 | 2014 |
| Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation E Schorb, B Kasenda, J Atta, S Kaun, A Morgner, G Hess, T Elter, ... haematologica 98 (5), 765, 2013 | 104 | 2013 |
| International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS … AJ Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ... Lancet Haematol 3 (5), e217-e227, 2016 | 98 | 2016 |
| High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German … B Kasenda, G Ihorst, R Schroers, A Korfel, I Schmidt-Wolf, G Egerer, ... Leukemia 31 (12), 2623-2629, 2017 | 86 | 2017 |
| Early atherosclerosis in childhood type 1 diabetes: role of raised systolic blood pressure in the absence of dyslipidaemia KO Schwab, J Doerfer, A Krebs, K Krebs, E Schorb, K Hallermann, ... European journal of pediatrics 166, 541-548, 2007 | 70 | 2007 |
| High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study E Schorb, CP Fox, K Fritsch, L Isbell, A Neubauer, A Tzalavras, ... Bone Marrow Transplantation 52 (8), 1113-1119, 2017 | 69 | 2017 |
| High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase … E Schorb, J Finke, AJM Ferreri, G Ihorst, K Mikesch, B Kasenda, K Fritsch, ... BMC cancer 16, 1-9, 2016 | 67 | 2016 |
| Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis AM Schmitt, AK Herbrand, CP Fox, K Bakunina, JEC Bromberg, ... Hematological oncology 37 (5), 548-557, 2019 | 66 | 2019 |
| Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, C Celico, ... Leukemia 36 (7), 1870-1878, 2022 | 62 | 2022 |
| Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients MR Wilson, TA Eyre, AA Kirkwood, N Wong Doo, C Soussain, S Choquet, ... Blood, The Journal of the American Society of Hematology 139 (16), 2499-2511, 2022 | 55 | 2022 |
| Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system–an international study of … E Schorb, CP Fox, B Kasenda, K Linton, N Martinez‐Calle, T Calimeri, ... British Journal of Haematology 189 (5), 879-887, 2020 | 52 | 2020 |
| 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma B Kasenda, V Haug, E Schorb, K Fritsch, J Finke, M Mix, C Hader, ... Journal of Nuclear Medicine 54 (2), 184-191, 2013 | 43 | 2013 |
| Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas JA Mutter, SK Alig, MS Esfahani, EM Lauer, J Mitschke, DM Kurtz, J Kühn, ... Journal of Clinical Oncology 41 (9), 1684-1694, 2023 | 41 | 2023 |
| High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study E Schorb, B Kasenda, G Ihorst, F Scherer, J Wendler, L Isbell, H Fricker, ... Blood advances 4 (14), 3378-3381, 2020 | 38 | 2020 |
